Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.56 |
| ▸ | ERBB2 | P04626 | 11/20 | 0.56 |
| ▸ | ERBB4 | Q15303 | 6/20 | 0.56 |
| ▸ | JAK3 | P52333 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22983382 | 0.86 | EGFR (0.51) | EGFRERBB2ERBB4JAK3KCNH2 | |
| SCHEMBL29718961 | 0.86 | EGFR (0.51) | EGFRERBB2ERBB4JAK3KCNH2 | |
| SCHEMBL22983387 | 0.86 | EGFR (0.51) | EGFRERBB2ERBB4JAK3KCNH2 | |
| SCHEMBL17200124 | 0.86 | EGFR (0.63) | EGFRERBB2ERBB4JAK3KCNH2 | |
| SCHEMBL17200125 | 0.86 | EGFR (0.63) | EGFRERBB2ERBB4JAK3KCNH2 | |
| SCHEMBL31638765 | 0.85 | EGFR (0.48) | EGFRERBB2ERBB4JAK3KCNH2 | |
| SCHEMBL24398908 | 0.84 | EGFR (0.49) | EGFRERBB2ERBB4JAK3KCNH2 | |
| SCHEMBL24398880 | 0.84 | EGFR (0.49) | EGFRERBB2ERBB4JAK3KCNH2 | |
| SCHEMBL22983932 | 0.84 | EGFR (0.49) | EGFRERBB2ERBB4JAK3KCNH2 | |
| SCHEMBL31638901 | 0.84 | EGFR (0.48) | EGFRERBB2ERBB4JAK3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022094464-A1 | METHOD OF TREATING CANCERS WITH ALKYNE SUBSTITUTED QUINAZOLINE DERIVATIVES | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2022-05-05 | — | — | WO | disclosed |